OR WAIT 15 SECS
BioClinica®, Inc., (NASDAQ: BIOC) announced that GlaxoSmithKline LLC (“GSK”) has signed a multi-year enterprise technology agreement to deploy BioClinica’s Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
“GSK had a requirement for a new solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident,” said Mark Weinstein, CEO of BioClinica. “We look forward to supporting GSK so that they can successfully deploy and utilize our software in their upcoming studies.”
Trident IWR’s design provides clinical operations personnel with a way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in less time than previously required. Trident IWR delivers rapid study setup without the need for programming, while delivering IVR (Interactive Voice Response) system phone support through the same configuration process.